Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer International Journal of Cell and Biomedical Science
AHMAD SULAIMAN LUBIS, AHMAD SULAIMAN
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Batasan Prostate Specific Antigen (PSA) pada Pasien Kanker Prostat untuk Memprediksi Metastasis ke Tulang di Rumah Sakit Sardjito, Yogyakarta LUBIS, AHMAD SULAIMAN
Indonesian Journal of Cancer Vol 8, No 4 (2014): Oct - Dec 2014
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (431.903 KB)

Abstract

The object of this study to establish a serum PSA cut-off value to predict the presence of bone metastasis in prostate cancer. Methods: Consecutive patients diagnosedwith prostate cancer were retrospectively analyzed. Patients had received bone scintigraphy and had their PSA concentration measured. The proper cut-off value was established based on statistical analysis in order to predict the possibility of bone metastasis among them. Results: eighty-three consecutive patients with prostate cancer were enrolled, and 55 patients (66%) with bone metastasis confirmed by scintigraphic findings. A serum PSA concentration of 17.65 ng/ml gave the best sensitivity (78.33%) and specificity (65.21%). The PPV and NPV were 85.45% and 53.57%, respectively (p<0.05) Conclusion: a cut-off value of 17.65 ng/ml appears to be an appropriate benchmark for stratifying metastatic bone disease in prostate cancer patientssuch that if a patient with newly diagnosed prostate cancer and without any skeletal symptoms has a serum PSA concentration of less than 17.65 ng/ml,we suggest that they would not need to undergo bone scintigraphy.
Intracavernous Stem Cell Injection for Erectile Dysfunction: Safety and Efficacy Review Lubis, Ahmad Sulaiman; Makarim, Fadhli Rizal; Aldiosta, Pradipta Hadyan
International Journal of Cell and Biomedical Science Vol 2 No 4 (2023)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v2i4.28

Abstract

Background: Erectile dysfunction is a common condition in men characterized by the inability to maintain an erectile state. Current treatment using phosphodiesterase-5 inhibitors treatment may leave significant side effects and effectivity problems in some patients. The use of stem cell transplantation in erectile dysfunction has been emerging as a replacement therapy for erectile dysfunction. The effectiveness of stem cell therapy for the treatment of erectile dysfunction has been investigated in several animal studies and one clinical trial in humans. The intracavernous injection is one of the methods to deliver stem cell treatment for erectile dysfunction besides intravenous and intraperitoneal. It was believed to improve erectile function by promoting cavernosal tissue regeneration, vascularization, and smooth muscle relaxation. However, the intracavernous injection of stem cells for erectile dysfunction treatment in clinical settings requires further investigation since its long-term efficacy and safety concerns regarding swelling, priapism, and fibrous plaque. Objective: This review aims to summarize the available evidence on the safety and efficacy of intracavernous stem cell injection for erectile dysfunction treatment in clinical studies only from PubMed. Conclusion: In conclusion, while the available evidence suggests that intracavernous stem cell injection is considered safe and effective for the treatment of erectile dysfunction, further large-scale clinical studies are needed to determine its long-term safety, efficacy, and optimal dosing regimens.
Co-Authors Aldiosta, Pradipta Hadyan Makarim, Fadhli Rizal